Fig. 4.
Fig. 4. Examination of the effects of the cAMP and PGE2 receptor agonists on MoDC migratory function. / Immature MoDCs (GM + IL-4) or MoDCs stimulated with the indicated stimuli for 2 days were examined for their migratory capacity toward CCL21 (6Ckine) (100 ng/mL) in transwell assays. (A) Migration toward CCL21 by immature MoDCs or MoDCs stimulated with either TNF-α + IFN-α ± PGE2 or ± forskolin (1 μM) or CD40L ± PGE2 or ± forskolin (1 μM). Data represent the mean ± SEM of triplicate wells from 5 separate donors. (B) Migration toward CCL21 by immature MoDCs or MoDCs stimulated with either PGE2, or TNF-α + IFN-α or +PGE2 or + the cAMP analogs dibutyryl-cAMP (db-cAMP) or 8-bromo-cAMP (1 μM) or + the PGE2 receptor agonists, 11-deoxy-PGE1 (11-d-PGE1) (EP2/EP4 agonist) or sulprostone (EP1/EP3 agonist) (1 μM). Data represent the mean ± SEM of triplicate wells and are representative of 3 separate experiments.

Examination of the effects of the cAMP and PGE2 receptor agonists on MoDC migratory function.

Immature MoDCs (GM + IL-4) or MoDCs stimulated with the indicated stimuli for 2 days were examined for their migratory capacity toward CCL21 (6Ckine) (100 ng/mL) in transwell assays. (A) Migration toward CCL21 by immature MoDCs or MoDCs stimulated with either TNF-α + IFN-α ± PGE2 or ± forskolin (1 μM) or CD40L ± PGE2 or ± forskolin (1 μM). Data represent the mean ± SEM of triplicate wells from 5 separate donors. (B) Migration toward CCL21 by immature MoDCs or MoDCs stimulated with either PGE2, or TNF-α + IFN-α or +PGE2 or + the cAMP analogs dibutyryl-cAMP (db-cAMP) or 8-bromo-cAMP (1 μM) or + the PGE2 receptor agonists, 11-deoxy-PGE1 (11-d-PGE1) (EP2/EP4 agonist) or sulprostone (EP1/EP3 agonist) (1 μM). Data represent the mean ± SEM of triplicate wells and are representative of 3 separate experiments.

Close Modal

or Create an Account

Close Modal
Close Modal